RecruitingNCT06577857
Inferonasal MIMS® Procedure: Long-Term Follow-Up Extension Study
Minimally Invasive Micro Sclerostomy (MIMS®) Inferonasal Procedure: Long-Term Follow-Up Extension Study
Sponsor
Sanoculis Ltd
Enrollment
53 participants
Start Date
Nov 4, 2022
Study Type
OBSERVATIONAL
Conditions
Summary
A long-term (24 and 30 months) follow-up extension, prospective, non-interventional, open label study for data collection from subjects who underwent prior MIMS® inferonasal surgery, in continuation of the previous clinical investigation with the MIMS® Device (MMS-EEU-5).
Eligibility
Min Age: 40 YearsMax Age: 85 Years
Inclusion Criteria1
- \. Subject who underwent MIMS® inferonasal procedure, and surgery was performed not earlier than 24 months from enrollment
Interventions
DEVICEInferonasal Minimally Invasive Micro Sclerostomy
The Inferonasal MIMS® procedure uses the proprietary MIMS® device, which creates a sclerostomy in the inferonasal quadrant of the eye.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06577857
Related Trials
Quality of Life After Glaucoma Surgery: Evaluating the Patient Perspective Across Surgical Options
NCT073032571 location
Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use
NCT072176781 location
AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension
NCT0449924849 locations
Comparative Effectiveness and Safety of ELIOS in Patients With Open-Angle Glaucoma Undergoing Cataract Surgery
NCT0624613616 locations
A Study to Evaluate Adverse Events and Change in Disease Activity With the XEN45 Glaucoma Treatment System Implantation In Adult Participants With Open-Angle Glaucoma in China
NCT0582185513 locations